MARSI | Disruptive technologies for effectively rehabilitating chronic ambulatory disability

Summary
Worlwide, about 60 million people have some kind of difficulty in walking, which is related to some neurological disorder
(stroke, dementia, neuromuscular diseases, etc). Roughly 40 million of affected correspond to elders and the % is higher in
Europe. The remaining is the sum of physically disabled by cerebral palsy (14 million), neuromuscular diseases (4 million),
spinal cord injury (paraplegia and quadriplegia, 3 million) and spina bifida (3 million).
Neurological disorders affect the lower motor of the nervous system and share the progressive muscle weakness, which
lead to several walk disability, loss of autonomy and psychosocial consequences. Most therapeutic treatments are limited to
medicines and musculoskeletal rehabilitation programs, which are very expensive and limited to 15-30 min/week
rehabilitation sessions.
Active lifestyle is the most effective measure to restore the physical conditions. But the loss of muscle strength impedes the
ambulatory function. The need is for a device allowing them walking effortlessly and safely in the everyday life activities.
Based on our ARES technology, -the minimal functional unit providing synchronized joints-muscles mobility- Marsi Bionics
has developed powered orthoses for in-house rehabilitation of patients affected by muscle weakness disorders, showing a
product portfolio that covers the needs of a wide range of Neurological Disorders. Marsi products will be commercialized
under renting models allowing patients acquiring it for daily use. This technology will improve these patients life quality and
enlarge life expectancy by avoiding critical health complications of losing walking ability.
Marsi is strengthened by joining with a leading company in the current industrial market, ESCRIBANO. This alliance in the
frame of SME Phase 2 will speed up industrialization, overcome the certification barrier and minimize the time to market. As
a result, we expect to reach above 36M€ turnover in 2023 and 81 generated jobs.
Unfold all
/
Fold all
More information & hyperlinks
Web resources: https://cordis.europa.eu/project/id/784498
Start date: 01-03-2018
End date: 28-02-2021
Total budget - Public funding: 2 499 150,00 Euro - 1 640 730,00 Euro
Cordis data

Original description

Worlwide, about 60 million people have some kind of difficulty in walking, which is related to some neurological disorder
(stroke, dementia, neuromuscular diseases, etc). Roughly 40 million of affected correspond to elders and the % is higher in
Europe. The remaining is the sum of physically disabled by cerebral palsy (14 million), neuromuscular diseases (4 million),
spinal cord injury (paraplegia and quadriplegia, 3 million) and spina bifida (3 million).
Neurological disorders affect the lower motor of the nervous system and share the progressive muscle weakness, which
lead to several walk disability, loss of autonomy and psychosocial consequences. Most therapeutic treatments are limited to
medicines and musculoskeletal rehabilitation programs, which are very expensive and limited to 15-30 min/week
rehabilitation sessions.
Active lifestyle is the most effective measure to restore the physical conditions. But the loss of muscle strength impedes the
ambulatory function. The need is for a device allowing them walking effortlessly and safely in the everyday life activities.
Based on our ARES technology, -the minimal functional unit providing synchronized joints-muscles mobility- Marsi Bionics
has developed powered orthoses for in-house rehabilitation of patients affected by muscle weakness disorders, showing a
product portfolio that covers the needs of a wide range of Neurological Disorders. Marsi products will be commercialized
under renting models allowing patients acquiring it for daily use. This technology will improve these patients life quality and
enlarge life expectancy by avoiding critical health complications of losing walking ability.
Marsi is strengthened by joining with a leading company in the current industrial market, ESCRIBANO. This alliance in the
frame of SME Phase 2 will speed up industrialization, overcome the certification barrier and minimize the time to market. As
a result, we expect to reach above 36M€ turnover in 2023 and 81 generated jobs.

Status

CLOSED

Call topic

SMEInst-06-2016-2017

Update Date

27-10-2022
Images
No images available.
Geographical location(s)
Structured mapping
Unfold all
/
Fold all
Horizon 2020
H2020-EU.2. INDUSTRIAL LEADERSHIP
H2020-EU.2.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
H2020-EU.2.1.1. INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
H2020-EU.2.1.1.0. INDUSTRIAL LEADERSHIP - ICT - Cross-cutting calls
H2020-SMEINST-1-2016-2017
SMEInst-06-2016-2017 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
H2020-SMEINST-2-2016-2017
SMEInst-06-2016-2017 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
H2020-EU.2.3. INDUSTRIAL LEADERSHIP - Innovation In SMEs
H2020-EU.2.3.1. Mainstreaming SME support, especially through a dedicated instrument
H2020-SMEINST-1-2016-2017
SMEInst-06-2016-2017 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
H2020-SMEINST-2-2016-2017
SMEInst-06-2016-2017 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
H2020-EU.3. SOCIETAL CHALLENGES
H2020-EU.3.1. SOCIETAL CHALLENGES - Health, demographic change and well-being
H2020-EU.3.1.4. Active ageing and self-management of health
H2020-EU.3.1.4.0. Cross-cutting call topics
H2020-SMEINST-1-2016-2017
SMEInst-06-2016-2017 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
H2020-SMEINST-2-2016-2017
SMEInst-06-2016-2017 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
H2020-EU.3.1.6. Health care provision and integrated care
H2020-EU.3.1.6.0. Cross-cutting call topics
H2020-SMEINST-1-2016-2017
SMEInst-06-2016-2017 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
H2020-SMEINST-2-2016-2017
SMEInst-06-2016-2017 Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well